Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial.

MLA

Morath, Christian, et al. “Individualised Immunosuppression with Intravenously Administered Donor-Derived Modified Immune Cells Compared with Standard of Care in Living Donor Kidney Transplantation (TOL-2 Study): Protocol for a Multicentre, Open-Label, Phase II, Randomised Controlled Trial.” BMJ Open, vol. 12, no. 11, Nov. 2022, p. e066128. EBSCOhost, https://doi.org/10.1136/bmjopen-2022-066128.

APA

Morath, C., Schmitt, A., Schmitt, M., Wang, L., Kleist, C., Opelz, G., Süsal, C., Tran, T. H., Scherer, S., Schwenger, V., Kemmner, S., Fischereder, M., Stangl, M., Hauser, I. A., Sommerer, C., Nusshag, C., Kälble, F., Speer, C., Benning, L., … Schaier, M. (2022). Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial. BMJ Open, 12(11), e066128. https://doi.org/10.1136/bmjopen-2022-066128

Chicago

Morath, Christian, Anita Schmitt, Michael Schmitt, Lei Wang, Christian Kleist, Gerhard Opelz, Caner Süsal, et al. 2022. “Individualised Immunosuppression with Intravenously Administered Donor-Derived Modified Immune Cells Compared with Standard of Care in Living Donor Kidney Transplantation (TOL-2 Study): Protocol for a Multicentre, Open-Label, Phase II, Randomised Controlled Trial.” BMJ Open 12 (11): e066128. doi:10.1136/bmjopen-2022-066128.